By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    benefits of using protein powder to build muscles
    Protein Powder for Muscle Mass: Everything You Need to Know
    December 12, 2021
    changes brought on by blockchain in healthcare
    Technology In The Healthcare Industry
    March 28, 2022
    What Does Core Body Temperature Say About Health?
    August 17, 2022
    Latest News
    Clean Your Mattress Properly to Avoid Common Health Issues
    March 29, 2023
    5 Benefits Of HIPAA-Compliant Answering Services
    March 28, 2023
    3 Ways To Deal With Health Issues In Cities With High Pollution
    March 22, 2023
    What Tools Should Your Caregiver Have?
    March 22, 2023
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    5 Things You Need to Do to Become a Better Nurse
    January 30, 2022
    Obesity – A Disease?
    August 24, 2017
    Alzheimer’s Plaques Might Begin in the Liver
    September 11, 2017
    Latest News
    What Are Bioidentical Hormones Made With?
    March 23, 2023
    Cover Medical Costs of Child Dog Bites with Legal Specialists
    March 23, 2023
    3 Ways to Improve the U.S. Healthcare System By 2030
    March 14, 2023
    6 Steps To Ensure Speed And Efficiency Of Clinical Studies
    March 14, 2023
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Obesity Drug Development and Market Outlook
Share
Sign In
Notification Show More
Latest News
healthy travel tips when visiting Australia
7 Essential Tips to Stay Safe and Healthy Visiting Australia
News
health risks of dirty mattress
Clean Your Mattress Properly to Avoid Common Health Issues
Health
eligble for NDIS?
Are You Eligible For NDIS? How To Apply
News
upgrade to your nursing career
4 Pertinent Ways to Upgrade Your Nursing Career
Nursing
career in nursing
8 Keys to A Fulfilling & Successful Career in Nursing
Career
Aa
Health Works CollectiveHealth Works Collective
Aa
Search
Have an existing account? Sign In
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Global Healthcare > Obesity Drug Development and Market Outlook
Global HealthcarePublic Health

Obesity Drug Development and Market Outlook

PatrickDriscoll
Last updated: 2011/07/18 at 2:56 PM
PatrickDriscoll
Share
6 Min Read
SHARE

Researchers theorize that the current increasing prevalence of obesity is primarily driven by the combination of sedentary lifestyles (i.e. the increasing prevalence of desk jobs over physical jobs, as well as lack of exercise during free time) and changes in diets, especially in developed countries. To date, pharmaceutical treatments have shown poor success rates. Efficacy has been lower than hoped for, with at best about 3-5% weight loss—not to be confused with percentage of excess weight loss, or %EWL, which is the clinical measure of obesity treatment success or failure.

Researchers theorize that the current increasing prevalence of obesity is primarily driven by the combination of sedentary lifestyles (i.e. the increasing prevalence of desk jobs over physical jobs, as well as lack of exercise during free time) and changes in diets, especially in developed countries. To date, pharmaceutical treatments have shown poor success rates. Efficacy has been lower than hoped for, with at best about 3-5% weight loss—not to be confused with percentage of excess weight loss, or %EWL, which is the clinical measure of obesity treatment success or failure.

Nevertheless, driven by the staggering potential market size, companies continue to work to develop efficacious and relatively safe pharmaceutical treatments for obesity. (See Report #S835 for specific drug candidates and products in development, on the market, or recently withdrawn market, and the current and future market status for these drugs, as well as devices for obesity management.)

More Read

emerging technology in healthcare

Benefits of Emerging Technology in Healthcare in 2023

Simplifying the Genetic Testing Process: How At-Home Kits are Changing the Game
Why a Health Retreat Can Be the Best Medicine
Best Money-Saving Tips for Health Managers
HR Must Navigate Polarizing Views in Healthcare Workplaces

Source: MedMarket Diligence, LLC

Pharmaceuticals for the treatment of obesity fall into a number of categories based on their functional approach to treating the condition.  These include appetite suppression, malabsorption, satiety and combinations of these (e.g., Orexigen’s Contrave).  There is some debate in the clinical literature as to whether there is adequate distinction between appetite suppression and satiety to consider them functionally different drugs.

Other drugs, such as Amylin’s Byetta, have been shown to reduce weight loss as a function of its role in managing type 2 diabetes.

Trials for pharmaceutical treatment of obesity are aggressive as drug makers aggressively seek to generate clinical data on drugs already developed that will illustrate safety and efficacy, an increasingly difficult hurdle to cross (some would say “moving target”) based on the past rejections by the FDA.

Given the challenges of past drug candidates in gaining approval, and considering the untapped opportunity for obesity drugs, companies are actively pursuing multiple alternative angles to solving the obesity drug challenge:

  • melanocortin receptor system
  • cannabinoid receptor antagonists
  • GLP-1 analogs
  • methionine aminopeptidase 2 (MetAP2) inhibitor

In order to be judged effective the FDA holds that an obesity drug must meet at least one of two endpoints:

  • At least 35% or more of patients on the drug must lose at least 5% of their body weight. This weight loss must be twice that for placebo, and the results must be statistically significant.
  • There must be ≥ 5% difference in the mean weight loss between the active product and the placebo group, and again the results must be statistically significant.

The FDA also says that it will look at several secondary efficacy endpoints. These include blood pressure, pulse, lipoprotein lipids, and fasting glucose and insulin. However, the FDA does not limit itself to these, and may examine other metabolic parameters. The manufacturer might not learn what those other parameters are until the time of the review, and perhaps not until receiving a negative recommendation from the committee reviewing the drug, and reading the complete response letter (CRL).

With regard to obesity drugs, the FDA appears to take the position that the patients who would receive such drugs are basically healthy, so any weight management product must not only show decent efficacy, it must have no risk of causing lasting and/or serious harm to the patient. Some marketing managers say that it should come as no great surprise that drugs which appeared to be strong contenders for approval—such as Vivus’ Qnexa and Arena’s lorcaserin—received negative recommendations, given the uncertainty involved in trying to adhere to ‘draft’ guidelines. These managers also point out that the FDA routinely approves pharmaceuticals for the market which are known to have side effects, apparently judging that the cure is less harmful than the disease. Is there, then, a degree of bias within the FDA against the pharmaceutical treatment of obesity? If so, is this situation likely to improve? Whether or not a bias exists, we forecast that during the next five years, the FDA will approve several drugs for the treatment of obesity.


See further details of the pharmaceutical industry’s development of obesity drugs at link.

     

TAGGED: global health, obesity, public health

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
PatrickDriscoll July 18, 2011
Share this Article
Facebook Twitter Copy Link Print
Share
By PatrickDriscoll
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Previous Article Elder Financial Abuse Spikes 12% Since 2008
Next Article Diagnosing an Illness With Facebook

Stay Connected

1.5k Followers Like
4.5k Followers Follow
2.8k Followers Pin
136k Subscribers Subscribe

Latest News

healthy travel tips when visiting Australia
7 Essential Tips to Stay Safe and Healthy Visiting Australia
News March 29, 2023
health risks of dirty mattress
Clean Your Mattress Properly to Avoid Common Health Issues
Health March 29, 2023
eligble for NDIS?
Are You Eligible For NDIS? How To Apply
News March 29, 2023
upgrade to your nursing career
4 Pertinent Ways to Upgrade Your Nursing Career
Nursing March 29, 2023

You Might also Like

US healthcare system
Global Healthcare

3 Ways to Improve the U.S. Healthcare System By 2030

March 14, 2023
Clinical Studies
Global Healthcare

6 Steps To Ensure Speed And Efficiency Of Clinical Studies

March 14, 2023
valueable healthcare programs
News

5 Most Valuable Healthcare Programs in 2023

March 8, 2023
everest healthcare
Global Healthcare

The Everest Foundation’s Mission to Support Inclusive Healthcare

February 24, 2023
//

We influence million of users and is the most authentic source of information on healthcare business and technology news.

Quick Links

  • About
  • Contact
  • Privacy
Subscribe

Subscribe to our newsletter to get our newest articles instantly!

Follow US

© 2008-2023 HealthWorks Collective. All Rights Reserved.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?